Cannabis product innovations today involve more than just delta-9 THC. Minor cannabinoids introduced within the U.S. CBD market, like CBG, CBN, THCV, and delta-8 THC, are establishing themselves on regulated cannabis dispensary shelves. These and other added cannabinoids allow brands to offer tailored experiences and differentiate themselves.
In the regulated cannabis space, CBN and CBG take up the lion’s share of minor cannabinoid products. Of cannabis products with a minor cannabinoid, 65% of them include CBN and 23% include CBG. These two non-psychoactive cannabinoids are said to interact with THC to contribute to the “entourage effect,” where minor cannabinoids interact with delta-9 THC within the body to create different psychoactive experiences. While more research is needed to confirm the effects of each, CBN is purported to enhance feelings of sleepiness and relaxation, and CBG is said to yield a more present, clear-headed experience, according to patient surveys.
